Rainwater Foundation Funds Three Tau Research Projects
The Fort Worth-based foundation awarded more than $1 million to three researchers pursuing preclinical drugs that target tau in neurodegenerative disease.
Updated on Nov. 10, 2026 in Alzheimer’s
The Rainwater Charitable Foundation granted over $1 million to three researchers developing preclinical drug candidates that target tau, a protein implicated in several neurodegenerative diseases. The one-year projects were funded through the foundation's 2026 Sprint to Lead drug discovery grant program.
Why it matters
Substantial gaps remain in turning tau-related scientific insights into therapies that deliver meaningful clinical benefit. Successful projects may generate the evidence needed to support later in vivo studies and investigational new drug-enabling work.
The foundation has invested over $165 million in medical research to date and helped advance eight treatments into human trials, while this round funds three one-year preclinical projects at $350,000 each. Whether these tau-targeting candidates will progress beyond the preclinical stage has not been determined.
The players
Rainwater Charitable Foundation
A Fort Worth, Texas-based philanthropic organization created in the early 1990s by Richard E. Rainwater that has invested over $165 million in medical research.
The details
Proposals were selected for their potential to advance promising preclinical therapeutic candidates targeting tau-driven neurodegenerative diseases, and the foundation encourages applications from interdisciplinary teams. The Sprint to Lead program focuses on the hit-to-lead and lead optimization phases of drug discovery.
Timeline
November 10, 2026: The Rainwater Charitable Foundation announced over $1 million in grants.
2027: Sprint to Lead letter of intent submissions open, with specific dates to be released in the coming months.
Roadmap
The grants are the first funded round of the Sprint to Lead program, which targets the hit-to-lead and lead optimization phases of drug discovery. The awards focus on tau, which underlies primary tauopathies such as progressive supranuclear palsy, corticobasal degeneration, Pick's disease, and certain forms of frontotemporal degeneration.
These awards are preclinical and will not produce new treatments available to patients in the near term. Their outcomes could eventually inform therapies for people affected by tau-driven neurodegenerative conditions.
The takeaway
Funding for tau-targeted preclinical work reflects an effort to close the gap between laboratory insight and clinical therapies for neurodegenerative disease. Readers following Alzheimer’s and related disorders should watch for later-stage results from these early-stage projects.
What happens next
The Rainwater Charitable Foundation will release letter of intent submission dates for the 2027 Sprint to Lead program in the coming months.
Further reading
Explore more on Alzheimer’s research and treatment developments in Texas.
Source note: This article includes information reported by Star Local.
